Clarivate's Portfolio Pivot: Selling Life Sciences to Double Down on AI-Native Research
A Strategic Divestiture Reshapes the Thesis
Clarivate’s second-quarter call delivered a clear inflection point: the announced sale of its Life Sciences & Healthcare segment to Altaris marks a decisive portfolio rationalization. As CEO Matti Shem Tov framed it, the move creates "a more focused company as a subscription-first provider," simplifying operations and allowing targeted investment in organic growth. The company now expects recurring revenue mix to rise from 89% to roughly 92% on a pro forma basis, a shift that improves predictability and cash-flow visibility.
Indeed, the financial results already show the pivot’s early effects. “The change in the quarter over the prior year was due to the inorganic disposals, lower organic transactional revenues, and a modest foreign exchange impact partially offset by organic recurring revenue growth.” — Jonathan Collins · 2026-07-29 Organic ACV grew 1.5% in Q2, with the Academia & Government and Life Sciences segments each delivering 2% growth, while the Intellectual Property segment held recurring revenue flat. The company is now guiding to a blended organic ACV growth of ~2.25% by year-end, with A&G approaching 3%.
AI-Native Products as the Growth Engine
The company’s confidence rests on a wave of new AI-powered offerings. The launch of Web of Science Research Intelligence, an AI-native platform for research strategy, has already generated "a multimillion-dollar ACV pipeline" and secured 77 paying customers. Meanwhile, Nexus Connect and IP-1, both agentic AI solutions, are designed to embed Clarivate’s proprietary data into customer workflows. “We are embedding Clarivate proprietary intelligence into existing research workflows for the academic community. It is leading to new revenue streams.” — Matti Shem Tov · 2026-07-29 This aligns with a broader industry trend toward Agentic AI adoption, but Clarivate’s edge lies in its decades of curated datasets and domain expertise.
The IP segment also gains renewed leadership with Simon Webster returning as president. His prior tenure at CPA Global delivered mid-single-digit organic growth, and management believes his expertise will accelerate the IP turnaround. Combined with the launch of IP-1, a unified AI platform for patent and trademark professionals, the segment is positioned for recovery. As Matti noted, "we are just going to disrupt the market using both our agentic capabilities and expertise and our proprietary data."
By and large, bigger customers would like to be able to embed this suite through MCP. Smaller customers may want to use it in our environment. But this is just early days overall.
From Transactional to Recurring
A key narrative is the deliberate shift away from one-time transactions. The divestiture accelerates this—LS&H contained some higher-transactional businesses—but management is also converting existing offerings like Web of Science batch files to subscription. This mirrors a broader market trend where recurring revenue growth is increasingly prized, yet Clarivate faces the challenge of near-term revenue declines as it laps prior transactional headwinds. In Q2, organic revenues fell $9 million, but disciplined cost management held adjusted EBITDA margin stable, and the company expects margins to expand ~200 bps for the full year.
The balance sheet is also being strengthened: the company repurchased $75 million of bonds in Q2 and plans to use LS&H proceeds to cut debt by about $900 million this year. This financial discipline supports the investment in AI innovation while providing flexibility for future shareholder returns.
Leadership changes underscore the transformation. Jonathan Collins is stepping down as CFO, succeeded by Michael Easton, who has been instrumental in the value creation plan. With a leaner portfolio, a stronger recurring base, and a clearer AI roadmap, Clarivate is signaling it has the building blocks to accelerate growth into 2027. “We expect sequential improvement in recurring organic growth in the second half of 2026 and continued momentum into 2027.” — Matti Shem Tov · 2026-07-29